beta

ALLO

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019 03-07-2019
Actual EPS -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35 -0.35
Consensus EPS -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23
Estimated EPS -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23 -0.23
Number of Estimates 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
EPS Surprise -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12 -$0.12

Stats

Summary

Market Cap:

Primary Exchange:

Website: /stocks/allo

Shares Outstanding:

Float:

Dividend: (%)

Beta:

Sector:

Industry:

Short Interest ():

Ethical Flags

Longest drawdown: 148 trading days

From: 2018-11-06 To: 2019-06-12

Lowest Point:

Allogene Therapeutics (ALLO) Investor Presentation - Slideshow

via: SeekingAlpha at 2019-06-06 09:56:11:000

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this Read more … read more...

Allogene Therapeutics (ALLO) Investor Presentation - Slideshow

via: SeekingAlpha at 2019-06-06 09:56:11:000

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this Read more … read more...

Allogene Therapeutics (ALLO) Investor Presentation - Slideshow

via: SeekingAlpha at 2019-06-06 09:56:11:000

The following slide deck was published by Allogene Therapeutics, Inc. in conjunction with this Read more … read more...

American Society Of Clinical Oncology: A Biotech Friendly Event In An Unfriendly Healthcare Market

via: SeekingAlpha at 2019-06-02 12:56:36:000

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais… read more...

American Society Of Clinical Oncology: A Biotech Friendly Event In An Unfriendly Healthcare Market

via: SeekingAlpha at 2019-06-02 12:56:36:000

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais… read more...

American Society Of Clinical Oncology: A Biotech Friendly Event In An Unfriendly Healthcare Market

via: SeekingAlpha at 2019-06-02 12:56:36:000

Market Pulse The month of May thus far has been mostly a downward ride with an occasional rise, proving to be a mere bunny bump, as indexes have eroded persistently on the lack of a trade resolution with China, an outcome that at one point was considered to be almost in the bag. This is rais… read more...

Wells Fargo likes Molina after Investor Day

via: SeekingAlpha at 2019-05-31 04:41:50:000

Allogene Therapeutics (NASDAQ: ALLO ) initiated with Neutral rating at Guggenheim. More news on: Allogene Therapeutics, Inc., Fate Therapeutics, Inc., Rubius Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

Wells Fargo likes Molina after Investor Day

via: SeekingAlpha at 2019-05-31 04:41:50:000

Allogene Therapeutics (NASDAQ: ALLO ) initiated with Neutral rating at Guggenheim. More news on: Allogene Therapeutics, Inc., Fate Therapeutics, Inc., Rubius Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...

3 Gene Therapy Stocks For A Biotech Portfolio

via: SeekingAlpha at 2019-05-20 08:53:25:000

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma… read more...

3 Gene Therapy Stocks For A Biotech Portfolio

via: SeekingAlpha at 2019-05-20 08:53:25:000

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma… read more...

3 Gene Therapy Stocks For A Biotech Portfolio

via: SeekingAlpha at 2019-05-20 08:53:25:000

Biotech Pulse The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have struggled since March as the broader healthcare sector ( XLV ) declined following growing momentum amongst the presidential candidates for a universal healthcare plan. This was at a time when the broader ma… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-11 11:30:11:000

Allogene Therapeutics, Inc. (ALLO) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Participa… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-11 11:30:11:000

Allogene Therapeutics, Inc. (ALLO) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Participa… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-11 11:30:11:000

Allogene Therapeutics, Inc. (ALLO) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Participa… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-11 11:30:11:000

Allogene Therapeutics, Inc. (ALLO) Q1 2019 Earnings Conference Call May 07, 2019 08:30 AM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Participa… read more...

Allogene Therapeutics beats by $0.12

via: SeekingAlpha at 2019-05-07 03:39:16:000

Allogene Therapeutics (NASDAQ: ALLO ): Q1 GAAP EPS of -$0.32 beats by $0.12 . More news on: Allogene Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Allogene Therapeutics beats by $0.12

via: SeekingAlpha at 2019-05-07 03:39:16:000

Allogene Therapeutics (NASDAQ: ALLO ): Q1 GAAP EPS of -$0.32 beats by $0.12 . More news on: Allogene Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Allogene Therapeutics beats by $0.12

via: SeekingAlpha at 2019-05-07 03:39:16:000

Allogene Therapeutics (NASDAQ: ALLO ): Q1 GAAP EPS of -$0.32 beats by $0.12 . More news on: Allogene Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Market At New Highs, But Healthcare And Biotechs Feel The Heat

via: SeekingAlpha at 2019-04-29 09:22:32:000

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Disney+ And Bank Majors Step Out (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-04-07 03:37:15:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you c… read more...

Stocks To Watch: Disney+ And Bank Majors Step Out

via: SeekingAlpha at 2019-04-06 04:39:00:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees a heavy dose of healthcare companies presenting at investor con… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-09 05:04:04:000

Allogene Therapeutics, Inc. (ALLO) Q4 2018 Earnings Conference Call March 8, 2019 8:30 P.M. ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Partici… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-09 05:04:04:000

Allogene Therapeutics, Inc. (ALLO) Q4 2018 Earnings Conference Call March 8, 2019 8:30 P.M. ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Partici… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-09 05:04:04:000

Allogene Therapeutics, Inc. (ALLO) Q4 2018 Earnings Conference Call March 8, 2019 8:30 P.M. ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Partici… read more...

Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q4 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-03-09 05:04:04:000

Allogene Therapeutics, Inc. (ALLO) Q4 2018 Earnings Conference Call March 8, 2019 8:30 P.M. ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President, Chief Executive Officer Eric Schmidt - Chief Financial Officer Conference Call Partici… read more...

Allogene Therapeutics misses by $0.05

via: SeekingAlpha at 2019-03-08 03:08:55:000

Allogene Therapeutics (NASDAQ: ALLO ): Q4 GAAP EPS of -$0.37 misses by $0.05. More news on: Allogene Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Poseida Therapeutics Files For U.S. IPO

via: SeekingAlpha at 2019-01-08 09:10:35:000

Quick Take Poseida Therapeutics ( PSTX ) intends to raise $115 million from the sale of its common stock in a U.S. IPO, per an S-1 registration statement . The company is advancing a pipeline of CAR-T treatment candidates for hematological cancers and solid tumors. PSTX has obtained pos… read more...

Poseida Therapeutics Files For U.S. IPO

via: SeekingAlpha at 2019-01-08 09:10:35:000

Quick Take Poseida Therapeutics ( PSTX ) intends to raise $115 million from the sale of its common stock in a U.S. IPO, per an S-1 registration statement . The company is advancing a pipeline of CAR-T treatment candidates for hematological cancers and solid tumors. PSTX has obtained pos… read more...

Poseida Therapeutics Files For U.S. IPO

via: SeekingAlpha at 2019-01-08 09:10:35:000

Quick Take Poseida Therapeutics ( PSTX ) intends to raise $115 million from the sale of its common stock in a U.S. IPO, per an S-1 registration statement . The company is advancing a pipeline of CAR-T treatment candidates for hematological cancers and solid tumors. PSTX has obtained pos… read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Morgan Stanley upgrades Teva and Bausch in premarket analyst action

via: SeekingAlpha at 2018-11-05 08:47:44:000

Fate Therapeutics (NASDAQ: FATE ) initiated with Buy rating and $17 (15% upside) at Jefferies. More news on: Fate Therapeutics, Inc., Allogene Therapeutics, Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Looking Beyond The Election (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-04 06:30:58:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Looking Beyond The Election

via: SeekingAlpha at 2018-11-03 09:26:43:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Yep, there is an election next week that's going to steal some headlines, but inves… read more...

Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

via: Business Wire at 2018-11-01 09:26:00:000

Data Provide Insights in Preparation for Investigational New Drug (IND) Submissions Planned in 2019 for ALLO-501 (anti-CD19) in Non-Hodgkin Lymphoma and ALLO-715 (anti-BCMA) in Multiple Myeloma Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pionee… read more...

Allogene Therapeutics Announces Data Presentations Supporting Its Allogeneic CAR T Pipeline Program at 60th American Society of Hematology (ASH) Annual Meeting

via: Business Wire at 2018-11-01 09:26:00:000

Data Provide Insights in Preparation for Investigational New Drug (IND) Submissions Planned in 2019 for ALLO-501 (anti-CD19) in Non-Hodgkin Lymphoma and ALLO-715 (anti-BCMA) in Multiple Myeloma Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pionee… read more...

Biotech IPOs on pace for near-record year - WSJ

via: SeekingAlpha at 2018-10-31 09:03:50:000

The Wall Street Journal reports that the pace of biotech IPOs in on track for a near-record year, although many are riskier due to being in earlier stages of development. The public funding rush has been heavily influenced by the FDA's willingness to accelerate approval for promising drugs… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-10-28 09:11:09:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look for… read more...

Apple Looks To Recharge Tech Sector

via: SeekingAlpha at 2018-10-27 08:44:22:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors are being put to the rest with major indexes now down sharply on the year… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Allogene closes $373M IPO

via: SeekingAlpha at 2018-10-15 16:47:01:000

Allogene Therapeutics (NASDAQ: ALLO ) has closed its IPO of 20.7M shares of common stock at $18 per share including the full exercise of underwriters' over-allotment of 2.7M shares. More news on: Allogene Therapeutics, Healthcare stocks news, IPO News, Read more … read more...

Allogene closes $373M IPO

via: SeekingAlpha at 2018-10-15 16:47:01:000

Allogene Therapeutics (NASDAQ: ALLO ) has closed its IPO of 20.7M shares of common stock at $18 per share including the full exercise of underwriters' over-allotment of 2.7M shares. More news on: Allogene Therapeutics, Healthcare stocks news, IPO News, Read more … read more...

Allogene closes $373M IPO

via: SeekingAlpha at 2018-10-15 16:47:01:000

Allogene Therapeutics (NASDAQ: ALLO ) has closed its IPO of 20.7M shares of common stock at $18 per share including the full exercise of underwriters' over-allotment of 2.7M shares. More news on: Allogene Therapeutics, Healthcare stocks news, IPO News, Read more … read more...

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-10-15 16:30:00:000

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock… read more...

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-10-15 16:30:00:000

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock… read more...

Allogene Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

via: Business Wire at 2018-10-15 16:30:00:000

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) therapies for cancer, today announced the closing of its previously announced initial public offering of 20,700,000 shares of its common stock… read more...

U.S. IPO Weekly Recap: Despite Sell-Off, 4 IPOs Price With Unicorn Anaplan Up 43%

via: SeekingAlpha at 2018-10-14 09:31:41:000

The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or below issue. One small SPAC priced. Anaplan priced $2 above the range and… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX